An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Insulet Corporation (NASDAQ: PODD) has announced its plans to release financial results for the fourth quarter and full year of 2022 on February 23, 2023, following market closure. The management will conduct a conference call at 4:30 p.m. ET on the same day, with access via the Company's Investor Relations website. Insulet is recognized for its Omnipod product platform, which offers innovative solutions for diabetes management, including the Omnipod® 5 Automated Insulin Delivery System. This groundbreaking system integrates with continuous glucose monitoring, bringing advanced insulin delivery to users.
Positive
Upcoming release of Q4 and full year 2022 financial results.
Integration of Omnipod 5 with continuous glucose monitoring enhances diabetes management.
Negative
None.
ACTON, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2022 on February 23, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers or (929) 203-2109 for international callers, passcode is 5904836.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
When will Insulet Corporation release its Q4 2022 financial results?
Insulet Corporation will release its Q4 2022 financial results on February 23, 2023.
What time is the conference call for Insulet's financial results?
The conference call for Insulet's financial results will be held at 4:30 p.m. ET on February 23, 2023.
How can I access the conference call for Insulet's financial results?
The conference call can be accessed via the Investor Relations section of Insulet's website or by dialing (888) 770-7129 for domestic callers.
What is the significance of the Omnipod 5 Automated Insulin Delivery System?
The Omnipod 5 integrates with continuous glucose monitors to simplify insulin delivery, allowing users to manage their diabetes without multiple daily injections.
